Red improvement of bishop health 2025 special drug demand for profit prediction

January 30 (Reuters) -Cardinal Health, a drug distributor, raised its profit forecast after the 2025 fiscal year on Thursday, because the strong demand for expensive special drugs and brand drugs promoted its sales of the drug department.

American drug distributors are strengthening their position in the special medical market. The focus of the market is to treat complex diseases, such as rheumatoid arthritis and cancer. The profit potential of these products has attracted these products.

Bishop Red said that earlier this month, it expects the annual profit to reach its high -end predictive scope.

The company now predicts that the adjusted profit is US $ 7.85 to $ 8.00 per share, and the previous range is US $ 7.75 to $ 7.90. According to the data of LSEG data, the points are less than $ 7.86 per share.

The bishop of Red has obtained a lot of income from the drug and professional solution department. Through the unit, it distributes brands and generic drugs, special drugs, and non -prescription drug health care and consumer products through the unit.

The company has been actively seeking diversification of transcendence of drug distribution, and has conducted a series of strategic acquisitions in 2024 to enter a higher growth medical field, such as cancer care, gastrointestinal disease and family medical care solutions.

This is after the major contract with the OptumRX loss with the pharmacy welfare management department of Unitedhealth Group in 2024.

According to LSEG data, according to the adjustment of the adjustment, Cardinal Health reported the profit of $ 1.93 per share in the quarter, defeating analysts’ estimated $ 1.76 per share.

The total sales of this company in Ohio were US $ 55.26 billion in the second quarter, while analysts estimated to be $ 55.02 billion.

(Report by Bandol’s Kamal Choudhury and Christy Santhosh; Edit of Tasim Zahid)